In MM, among potential targets, BCMA, CD38, SMALF7, FcRH5, and G protein-coupled receptor (GPCR) GPRC5D, have been selected to develop anti-MM BiTEs, with BCMA representing the most promising target. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.